Secondary osteoporosis: A review of the recent evidence

Endocrine Practice

Volumn 12, Issue 4, 2006, Pages 436-445

  Painter, Stephanie E ^a   Kleerekoper, Michael ^b   Camacho, Pauline M ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CORTICOSTEROID; CYCLOSPORIN; GONADORELIN; GONADORELIN AGONIST; HEPARIN; IMMUNOSUPPRESSIVE AGENT; ORAL CONTRACEPTIVE AGENT; PHENOBARBITAL; PHENYTOIN; PREDNISOLONE; PRIMIDONE; RALOXIFENE; TSUKUBAENOLIDE; VITAMIN D;

ANDROGEN THERAPY; BONE DENSITY; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CUSHING SYNDROME; FRACTURE; GASTROINTESTINAL DISEASE; HEMATOLOGIC DISEASE; HUMAN; HYPERTHYROIDISM; HYPOGONADISM; IDIOPATHIC HYPERCALCIURIA; ORGAN TRANSPLANTATION; PARATHYROIDECTOMY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PREMENOPAUSE; PRIMARY HYPERPARATHYROIDISM; REVIEW; RISK FACTOR; SECONDARY HYPERPARATHYROIDISM; SECONDARY OSTEOPOROSIS; VITAMIN D DEFICIENCY; CHEMICALLY INDUCED DISORDER; HYPERCALCEMIA; OSTEOPOROSIS; URINE;

ADRENAL CORTEX HORMONES; ANTICONVULSANTS; CUSHING SYNDROME; GASTROINTESTINAL DISEASES; HEMATOLOGIC DISEASES; HUMANS; HYPERCALCEMIA; HYPERPARATHYROIDISM, PRIMARY; HYPERTHYROIDISM; HYPOGONADISM; IMMUNOSUPPRESSIVE AGENTS; ORGAN TRANSPLANTATION; OSTEOPOROSIS; VITAMIN D DEFICIENCY;

EID: 33750118602     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.12.4.436     Document Type: Review

References (100)

1. Bilezikian JP. Osteoporosis in men. J Clin Endocrinol Metab. 1999;84:3431-3434.
2. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785-795.
3. Harper KD, Weber TJ. Secondary osteoporosis: diagnostic considerations. Endocrinol Metab Clin North Am. 1998;27:325-348.
4. Moreira Kulak CA, Schussheim DH, McMahon DJ, et al. Osteoporosis and low bone mass in premenopausal and perimenopausal women. Endocr Pract. 2000;6:296-304.
5. Stein E, Shane E. Secondary osteoporosis. Endocrinol Metab Clin North Am. 2003;32:115-134, vii.
6. Khosla S, Bilezikian JP. The role of estrogens in men and androgens in women. Endocrinol Metab Clin North Am. 2003;32:195-218.
7. Falahati-Nini A, Riggs BL, Atkinson EJ, O'Fallon WM, Eastell R, Khosla S. Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. J Clin Invest. 2000;106:1553-1560.
8. Leder BZ, LeBlanc KM, Schoenfeld DA, Eastell R, Finkelstein JS. Differential effects of androgens and estrogens on bone turnover in normal men. J Clin Endocrinol Metab. 2003;88:204-210.
9. Barrett-Connor E, Mueller JE, Von Muhlen DG, Laughlin GA, Schneider DL, Sartoris Dj. Low levels of estradiol are associated with vertebral fractures in older men, but not women: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2000;85:219-223.
10. Gennari L, Merlotti D, Martini G, et al. Longitudinal association between sex hormone levels, bone loss, and bone turnover in elderly men. J Clin Endocrinol Metab. 2003;88:5327-5333.
11. Mittan D, Lee S, Miller E, Perez RC, Basler JW, Bruder JM. Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab. 2002;87:3656-3661.
12. Stoch SA, Parker RA, Chen L, et al. Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. J Clin Endocrinol Metab. 2001;86: 2787-2791.
13. Basaria S, Lieb J II, Tang AM, et al. Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf). 2002;56:779-786.
14. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.
15. Lopez AM, Pena MA, Hernandez R, Val F, Martin B, Riancho JA. Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int. 2005;16: 707-711.
16. Grinspoon S, Thomas E, Pitts S, et al. Prevalence and predictive factors for regional osteopenia in women with anorexia nervosa. Ann Intern Med. 2000; 133:790-794.
17. Warren MP, Brooks-Gunn J, Fox RP, Holderness CC, Hyle EP, Hamilton WG. Osteopenia in exercise-associated amenorthea using ballet dancers as a model: a longitudinal study. J Clin Endocrinol Metab. 2002;87:3162-3168.
18. Soyka LA, Grinspoon S, Levitsky LL, Herzog DB, Klibanski A. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab. 1999;84:4489-4496.
19. Soyka LA, Misra M, Frenchman A, et al. Abnormal bone mineral accrual in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab. 2002;87:4177-4185.
20. Seeman E, Szmukler GI, Formica C, Tsalamandris C, Mestrovic R. Osteoporosis in anorexia nervosa: the influence of peak bone density, bone loss, oral contraceptive use, and exercise. J Bone Miner Res. 1992;7:1467-1474.
21. Gordon CM, Grace E, Emans SJ, et al. Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab. 2002;87:4935-4941.
22. Grinspoon S, Thomas L, Miller K, Herzog D, Klibanski A. Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa. J Clin Endocrinol Metab. 2002;87:2883-2891.
23. Saag KG. Glucocorticoid-induced osteoporosis. Endocrinol Metab Clin North Am. 2003;32:135-157, vii.
24. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996;313:344-346.
25. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15:993-1000.
26. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med. 1990;112:352-364.
27. Pearce G, Tabensky DA, Delmas PD, Baker HW, Seeman E. Corticosteroid-induced bone loss in men, J Clin Endocrinol Metab. 1998;83:801-806.
28. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis. 1995;54:49-52.
29. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000;39:1383-1389.
30. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345:941-947.
31. Wong CA, Walsh LJ, Smith CJ, et al. Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet. 2000;355:1399-1403.
32. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145:1835-1841.
33. Muir JM, Andrew M, Hirsh J, et al. Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood. 1996;88:1314-1320.
34. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol. 1993; 168:1265-1270.
35. Tannirandorn P, Epstein S. Drug-induced bone loss. Osteoporos Int. 2000; 11:637-659.
36. Carlin AJ, Farquharson RG, Quenby SM, Topping J, Fraser WD. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod. 2004;19:1211-1214.
37. Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, EI-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology. 2002;58:1348-1353.
38. Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology. 2004;62:2051-2057.
39. Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia. 2004;45:1330-1337.
40. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation [erratum in J Clin Endocrinol Metab. 2005;90:4118]. J Clin Endocrinol Metab. 2005;90:2456-2465.
41. Cohen A, Shane E. Osteoporosis after solid organ and bone marrow transplantation. Osteoporos Int. 2003;14: 617-630.
42. Monegal A, Navasa M, Guanabens N, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int. 2001; 68:83-86.
43. Patel S, Kwan JT, McCloskey E, et al. Prevalence and causes of low bone density and fractures in kidney transplant patients. J Bone Miner Res. 2001; 16:1863-1870.
44. Jodar E, Munoz-Torres M, Escobar-Jimenez F, Quesada-Charneco M, Lund del Castillo JD. Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clin Endocrinol (Oxf). 1997;47:279-285.
45. Kumeda Y, Inaba M, Tabara H, et al. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. J Clin Endocrinol Metab. 2000;85:4157-4161.
46. Karga H, Papapetrou PD, Korakovouni A, Papandroulaki F, Polymeris A, Pampouras G. Bone mineral density in hyperthyroidism. Clin Endocrinol (Oxf). 2004;61:466-472.
47. Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.
48. Lips P, Duong T, Oleksik A, et al. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the Multiple Outcomes of Raloxifene Evaluation clinical trial [erratum in J Clin Endocrinol Metab. 2001;86:3008]. J Clin Endocrinol Metab. 2001;86:1212-1221.
49. Kleerekoper M, Edelson GW. Biochemical studies in the evaluation and management of osteoporosis: current status and future prospects. Endocr Pract. 1996;2:13-19.
50. Mezquita-Raya P, Munoz-Torres M, Luna JD, et al. Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Miner Res. 200 1; 16:1408-1415.
51. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int. 1997;7:439-443.
52. Sahota O, Masud T, San P, Hosking DJ. Vitamin D insufficiency increases bone turnover markers and enhances bone loss at the hip in patients with established vertebral osteoporosis. Clin Endocrinol (Oxf). 1999;51:217-221.
53. Mosekilde L. Vitamin D and the elderly. Clin Endocrinol (Oxf). 2005;62:265-281.
54. Adams JS, Kantorovich V, Wu C, Javanbakht M, Hollis BW. Resolution of vitamin D insufficiency in osteopenic patients results in rapid recovery of bone mineral density. J Clin Endocrinol Metab. 1999;84:2729-2730.
55. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med, 1997;337:670-676.
56. Favus MJ. Postmenopausal osteoporosis and the detection of so-called secondary causes of low bone density. J Clin Endocrinol Metab. 2005;90:3800-3801.
57. Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab. 2005;90:3215-3224.
58. Passeri G, Pini G, Troiano L, et al. Low vitamin D status, high bone turnover, and bone fractures in centenarians. J Clin Endocrinol Metab. 2003;88:5109-5115.
59. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777-783.
60. Tangpricha V, Pearce EN, Chen TC, Holick MF. Vitamin D insufficiency among free-living healthy young adults. Am J Med. 2002; 112:659-662.
61. Bell NH, Jackson GJ. Role of vitamin D in the pathogenesis and treatment of osteoporosis. Endocr Pract. 1995;1:44-47.
62. Levis S, Gomez A, Jimenez C, et al. Vitamin D deficiency and seasonal variation in an adult South Florida population. J Clin Endocrinol Metab. 2005;90:1557-1562.
63. Syed Z, Khan A. Skeletal effects of primary hyperparathyroidism. Endocr Pract. 2000;6:385-388.
64. Khan A, Bilezikian J. Primary hyperparathyroidism: pathophysiology and impact on bone. CMAJ. 2000;163: 184-187.
65. Bilezikian JP, Potts JT Jr, Fuleihan G-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Clin Endocrinol Metab. 2002;97:5353-5361.
66. Sitges-Serra A, Girvent M, Pereira JA, et al. Bone mineral density in menopausal women with primary hyperparathyroidism before and after parathyroidectomy. World J Surg. 2004;28:1148-1152.
67. Khosla S, Melton LJ III Wermers RA, Crowson CS, O'Fallon W, Riggs B. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14:1700-1707.
68. Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341:1249-1255.
69. Rao DS, Phillips ER, Divine GW, Talpos GB. Randomized controlled clinical trial of surgery versus no surgery in patients with mild asymptomatic primary hyperparathyroidism. J Clin Endocrinol Metab. 2004;89:5415-5422.
70. Vestergaard P, Mosekilde L. Cohort study on effects of parathyroid surgery on multiple outcomes in primary hyperparathyroidism. BMJ. 2003;327:530-534.
71. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997; 103:197-207.
72. Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med. 1996; 101:262-269.
73. Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant. 2000; 19:736-743.
74. Ninkovic M, Love SA, Tom B, Alexander GJ, Compston JE. High prevalence of osteoporosis in patients with chronic liver disease prior to liver transplantation. Calcif Tissue Int. 2001;69:321-326.
75. Shane E, Rivas M, McMahon DJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab. 1997;82:1497-1506.
76. Floreani A, Fries W, Luisetto G, et al. Bone metabolism in orthotopic liver transplantation: a prospective study. Liver Transpl Surg. 1998;4:311-319.
77. Hussaini SH, Oldroyd B, Stewart SP, et al. Regional bone mineral density after orthotopic liver transplantation. Eur J Gastroenterol Hepatol. 1999; 11: 157-163.
78. Rodino MA, Shane E. Osteoporosis after organ transplantation. Am J Med. 1998; 104:459-469.
79. Leidig-Bruckner G, Hosch S, Dodidou P, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet, 2001;357:342-347,
80. Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease. J Clin Gastroenterol. 2004;38:218-224.
81. Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J Intern Med. 2000; 247:63-70.
82. Bernstein CN, Blanchard JF, Leslie W, Wajda A, Yu BN. The incidence of fracture among patients with inflammatory bowel disease: a population-based cohort study. Ann Intern Med. 2000;133:795-799,
83. Silvennoinen JA, Karttunen TJ, Niemela SE, Manelius JJ, Lehtola JK. A controlled study of bone mineral density in patients with inflammatory bowel disease. Gut. 1995; 37:71-76.
84. Vasquez H, Mazure R, Gonzalez D, et al. Risk of fractures in celiac disease patients: a cross-sectional, case-control study. Am J Gastroenterol. 2000;95:183-189.
85. Selby PL, Davies M, Adams JE, Mawer EB. Bone loss in celiac disease is related to secondary hyperparathyroidism. J Bone Miner Res. 1999; 14:652-657.
86. Meyer D, Stavropolous S, Diamond B, Shane E, Green PH. Osteoporosis in a North American adult population with celiac disease. Am J Gastroenterol. 2001;96:112-119.
87. Stenson WF, Newberry R, Lorenz R, Baldus C, Civitelli R. Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med. 2005;165:393-399.
88. Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nationwide follow-up study of 16,416 patients in Denmark. Am J Epidemiol. 2002;156:1-10.
89. Abrahamsen B, Andersen I, Christensen SS, Skov Madsen J, Brixen K. Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study. BMJ. 2005;330:818.
90. Melton LJ III, Kyle RA, Achenbach SJ, Oberg AL, Rajkumar SV. Fracture risk with multiple mycloma: a population-based study. J Bone Miner Res. 2005;20:487-493.
91. Dennison E, Hindmarsh P, Fall C, et al. Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. J Clin Endocrinol Metab. 1999;84: 3058-3063.
92. Reynolds RM, Dennison EM, Walker BR, et al. Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcif Tissue Int. 2005;77:134-138.
93. Hadjidakis D, Tsagarakis S, Roboti C, et al. Does subclinical hypercortisolism adversely affect the bone mineral density of patients with adrenal incidentalomas? Clin Endocrinol (Oxf). 2003;58:72-77.
94. Cortet B, Cortet C, Blanckaert F, et al. Quantitative ultrasound of bone and markers of bone turnover in Cushing's syndrome. Osteoporos Int. 2001;12:117-123.
95. Minetto M, Reimondo G, Osella G, Ventura M, Angeli A, Terzolo M. Bone loss is more severe in primary adrenal than in pituitary-dependent Cushing's syndrome. Osteoporos Int. 2004; 15:855-86 1.
96. Levy FL, Adams-Huet B, Pak CY. Ambulatory evaluation of nephrolithiasis: an update of a 1980 protocol. Am J Med. 1995;98:50-59.
97. Garcia-Nieto V, Navarro JF, Monge M, Garcia-Rodriguez VE. Bone mineral density in girls and their mothers with idiopathic hypercalciuria. Nephron Clin Pract. 2003;94:c89-c93.
98. Tasca A, Cacciola A, Ferrarese P, et al. Bone alterations in patients with idiopathic hypercalciuria and calcium nephrolithiasis. Urology. 2002;59:865-869.
99. Misael da Silva AM, dos Reis LM, Pereira RC, et al. Bone involvement in idiopathic hypercalciuria. Clin Nephrol. 2002;57:183-191.
100. Tannenbaum C, Clark J, Schwartzman K, et al, Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87:4431-4437.